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Abstract
The current SIOP treatment protocol for Wilms’ tumor involves pre-operative chemotherapy followed by nephrectomy. Not
all patients benefit equally from such chemotherapy. The aim of this study was to generate a miRNA profile of chemo
resistant blastemal cells in high risk Wilms’ tumors which might serve as predictive markers of therapeutic response at the
pre-treatment biopsy stage. We have shown here that unsupervised hierarchical clustering of genome-wide miRNA
expression profiles can clearly separate intermediate risk tumors from high risk tumors. A total of 29 miRNAs were
significantly differentially expressed between post-treatment intermediate risk and high risk groups, including miRNAs that
have been previously linked to chemo resistance in other cancer types. Furthermore, 7 of these 29 miRNAs were already at
the pre-treatment biopsy stage differentially expressed between cases ultimately deemed intermediate risk compared to
high risk. These miRNA alterations include down-regulation in high risk cases of miR-193a.5p, miR-27a and the up-regulation
of miR-483.5p, miR-628.5p, miR-590.5p, miR-302a and miR-367. The demonstration of such miRNA markers at the pre-
treatment biopsy stage could permit stratification of patients to more tailored treatment regimens.
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Introduction
Wilms’ Tumor (nephroblastoma), the commonest pediatric
renal tumor, arises predominantly in children under 5 years old,
and is thought to develop from embryonic kidney cells [1,2]. Of all
the embryonal tumors, Wilms’ represents the best example of
organogenesis ’’gone awry’’, as it contains varying amounts of the
triphasic elements of nephrogenesis including epithelial, stromal
and blastemal cell types, which are recognisable by light
microscopy.
Overall, outcomes for Wilms’ tumor are excellent and a current
key aim is the minimisation of therapy in these very young patients
to avoid long-term sequelae [3]. The current SIOP (Societe
Internationale d’Oncologie Paediatrique) protocol for the treat-
ment of Wilms’ Tumor in patients over the age of 6 months
includes neoadjuvant chemotherapy followed by nephrectomy [4].
The rationale is to down-stage tumors pre-operatively in order to
facilitate safer nephrectomy [5,6]. Post-nephrectomy, histological
evaluation permits staging and risk-based stratification. According
to the CCLG [Children’s Cancer and Leukaemia Group]
protocol, up-front diagnostic biopsy of the tumor is additionally
performed; thus therapy-naı¨ve tissue is evaluable in such cases.
There are currently no means at biopsy stage of identifying which
cases will be ‘blastemal’ and so deemed high-risk at nephrectomy.
Along with morphologically identified diffusely anaplastic cases
[known to be associated with TP53 mutation], blastemal Wilms’
represent the chemo-resistant cohort requiring more intensive
adjuvant chemotherapy. Studies that consider the molecular
mechanisms of chemo-resistance in Wilms’ tumor have focused
almost exclusively on gene expression profiling with no evidence of
signatures that might predict chemotherapeutic response [7].
Evidence is emerging for the role of miRNAs in both renal
development [8] and Wilms’ tumor progression [9]. Given the lack
of clear genomic/genetic pointers, our aim was to identify markers
of chemo resistance in Wilms’ tumor by miRNA profiling.
Materials and Methods
Patient Samples
In this study, the term chemo responsiveness is based on
histological findings such that intermediate risk cases are
considered to have shown better response, while high risk cases
showed relative resistance. The patient cohort (Table 1) initially
included 18 pre-treatment biopsy specimens and 27 post-
treatment nephrectomy specimens taken from patients who had
undergone neoadjuvant chemotherapy. Of these post-treatment
specimens, 13 represented intermediate risk cases [Post-IR-NBl],
where a response to chemotherapy was evidenced histologically by
the presence of cellular maturation whereas persistent blastema
was of limited proportion. The remaining 14 specimens were
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deemed high risk [Post-HR] or non-chemo responsive, due to
blastemal histology. The pre-treatment group comprised 4 tumor
biopsy samples from patients who were ultimately deemed high
risk [Pre-HR] and 14 which were ultimately intermediate risk
[Pre-IR]. Full face unstained sections of formalin-fixed, paraffin-
embedded tissue were cut, and following the review of correspond-
ing haematoxylin and eosin-stained sections, blastemal cells were
selectively isolated by macro-dissection from all pre-treatment
biopsies [Pre-IR and Pre-HR] and the 14 post-treatment high risk
specimens [Post-HR]. For the 13 post-treatment intermediate risk
specimens, the epithelial and/or stromal components were isolated
for analysis [Post-IR-NBl]. Subsequently, an additional group of
12 post-treatment intermediate risk cases were added to the
cohort, from which blastemal tissue was selectively isolated [Post-
IR-Bl].
miRNA Profiling Using TaqMan Low Density Arrays
Total RNA was extracted according to the manufacturer’s
instructions using RecoverAll Total Nucleic Acid Isolation Kit
(Ambion) which recovers the small RNA fraction and allows for
the downstream analysis of miRNAs. RNA was reverse tran-
scribed using the miRNA reverse transcription kit (Applied
Biosystems). Megaplex primer pool A used in this reaction
corresponds to TaqMan Low Density Array (TLDA) A (Applied
Biosystems), and allows the simultaneous reverse transcription of
377 miRNAs, 3 endogenous controls and 1 miRNA assay
unrelated to mammalian species on TLDA A. Alternatively, for
the individual analysis of miRNAs using Taqman miRNA assays,
target-specific stem-loop RT primers were used in combination
with the miRNA reverse transcription kit. Megaplex RT product
was pre-amplified using TaqMan PreAmp Master Mix (26) and
PreAmp Primer Pool A (Applied Biosystems). The PreAmp primer
pool contains forward primers specific for the miRNAs on TLDA
A and a universal reverse primer (Applied Biosystems). Each
cDNA sample was analyzed on TLDA A using the 7900HT RT-
qPCR system (Applied Biosystems).
Statistical and Bioinformatic Analysis
Ct values and Relative quantities were calculated using RQ
Manager 1.2.1 with the application of automatic baseline settings
and a threshold of 0.2. Prior to analysis samples were first
standardized (mean centred) and the normalized relative expres-
sion (NRQ) values of miRNA were calculated with reference to the
Ct max (maximum Ct value of a miRNA across samples) using the
equation NRQ = 2(Ctmax2Ct). MiRNAs that were expressed in at
least 10 samples were retained for analysis.
The combined hierarchical clustering was carried out using
Spearman’s rank correlation as an object similarity metric and
complete linkage was implemented to ascertain cluster similarity
using the hclust function. The associated heatmap analysis was
implemented using the heatmap.plus function. Colors were gener-
ated in a standardized manner using the rank of miRNA
expression values across samples.
The non-parametric Wilcoxon’s rank sum was used to measure
the significance of association of miRNA expression to the various
selected sample classes. P-values were corrected for multiple
comparisons using the Bonferroni method. Potential targeting of
differentially expressed miRNA and diametrically, differentially
expressed mRNA was examined by assessing the number of
predicted targets present. The significance of this value was
calculated by comparing this with that expected by chance using
Chi-squared statistic. This analysis was carried out using an
algorithm implemented Java v1.5 and the TargetScan version 5.1
database.
Results
In this study, the intermediate risk cases were defined, as
patients whose tumors were histologically regressive, epithelial,
stromal or mixed, post-chemotherapy. Of these, 69% were of
mixed histology, 15% stromal, 8% epithelial and 8% regressive.
The high risk group comprised blastemal cases only. Anaplastic
cases were deliberately excluded from this analysis, on the basis
that these tumors are driven, at least in part, by TP53 mutation
and are also readily recognisable microscopically. This patholog-
ical stratification parallels the clinical outcomes. Within our high
risk blastemal group, 28.6% of patients relapsed and a 78.6% 2
year survival is evident, whereas within the intermediate risk
group, there is a 100% 2 year survival and only 15.4% of patients
relapsed. The average ages of patients within high and in-
termediate risk groups are 46 months and 45 months respectively.
In order to assess the miRNA profiles of intermediate and high
risk groups, genome-wide miRNA expression analysis was
performed using TaqMan Low Density Array A, which includes
377 miRNAs and of these, 295 miRNAs were retained for
analysis. Unsupervised hierarchical clustering performed on these
295 miRNAs separates tumors into two clusters that clearly
discriminate high risk [A] from intermediate risk [B] cases. Sub-
clusters further discriminate between 4 pre- and 13 post-treatment
high risk groups (A1 and A2) and again between 14 pre- and 13
post-treatment intermediate risk groups (B2 and B1). Only one
post-treatment high risk tumor was mis-classified by this analysis
(Figure 1).
Following these initial observations, further unsupervised
clustering analysis was also performed. This analysis includes an
additional group of post-treatment intermediate risk cases, from
which the residual blastemal component had been isolated [Post-
IR-Bl], and results in the disruption of the distinct clustering
patterns observed between intermediate and high-risk groups in
Figure 1. Based on this analysis of miRNA expression profiles,
blastema from post-treatment intermediate risk cases [Post-IR-Bl],
Table 1. Sample Cohort.
Group name Short name Sample source Cell type Treatment administration Sample number
Pre-treatment High-risk Pre-HR Biopsy Blastemal Pre-treatment 4
Pre-treatment Intermediate-risk Pre-IR Biopsy Blastemal Pre-treatment 14
Post-treatment High-risk Post-HR Nephrectomy Blastemal Post-treatment 14
Post-treatment Intermediate-risk Post-IR-NBl Nephrectomy Epithelial/Stromal Post-treatment 13
Post-treatment Intermediate-risk Post-IR-Bl Nephrectomy Blastemal Post-treatment 12
doi:10.1371/journal.pone.0053417.t001
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appears most similar to blastema originating from pre-treatment
high risk blastemal cases [Pre-HR]. This is illustrated as
supporting information in Figure S1.
We assessed the miRNA expression differences between residual
blastema isolated from post-treatment intermediate risk cases
[Post-IR-Bl] and post-treatment high risk blastema [Post-HR-Bl].
This analysis identified 10 miRNAs (miR-551b, miR-106b, miR-
24, miR-542.3p, miR-331.3p, miR-223, miR-518b, miR-25, miR-
30b, miR-523) with significantly higher expression in high risk
cases (Table 2). The assumption here is that such miRNAs
somehow confer survival/proliferative advantage on blastemal
cells, allowing more thereof to survive chemotherapy in the high-
risk group.
The principal aim of this study was to identify miRNAs that are
predictive of chemotherapeutic response at the biopsy stage, and
which might then be used to stratify patients prior to the
administration of pre-nephrectomy chemotherapy. In order to
address this, we compared miRNA profiles of the non-blastemal
elements of post-treatment intermediate risk cases [Post-IR-NBl],
with post-treatment high risk tumor blastema [Post-HR]; essen-
tially comparing cells that have shown response with those that
have not. A total of 29 miRNAs differentially expressed between
non-blastemal elements of intermediate risk cases (Post-IR-NBl)
and high risk blastemal cases were identified (excluding major and
minor forms of the same miRNA), with 15 miRNAs down-
regulated and 14 miRNAs up-regulated in post-treatment high risk
[Post-HR] cases (p =#0.05) (Tables 3). We investigated for
representation of these miRNAs at the biopsy stage, through
comparison of pre-treatment biopsies originating from intermedi-
ate risk cases [Pre-IR], to pre-treatment biopsies from high risk
cases [Pre-HR]. Interestingly, 7 miRNAs from the post-treatment
analysis were also differentially expressed at the biopsy stage
(Table 4). Although the pre-treatment analysis did not yield any
significant p-values, perhaps due to the small sample size of the
pre-treatment high risk group, a total of 54 miRNAs approached
significance (p = 0.19).
In order to focus on potential markers of chemo resistance in
Wilms’ tumor we considered further the 7 miRNAs that were
found in this study to be significantly altered between intermediate
risk and high risk groups post-treatment, and also already
differentially expressed in the pre-treatment analyses. Our
assumption is that these miRNAs may be particularly important
indicators of the tumor’s potential to respond to pre-operative
chemotherapy. These miRNA alterations included the down-
regulation of miR-193a.5p and miR-27a, and the up-regulation of
miR-483.5p, miR-628.5p, miR-590.5p, miR-302a and miR-367
in high risk cases (Table 4). Although miR-20a expression was
altered in both pre- and post-treatment analyses the directional
changes were not consistent and therefore this miRNA was not
considered further.
Discussion
According to the SIOP protocol, standard management of renal
tumors is pre-operative chemotherapy followed by nephrectomy.
Although in most cases of Wilms’ tumor such therapy induces
a considerable degree of tumor shrinkage with evidence of necrosis
and cellular differentiation, a proportion of cases show lesser
volume reduction and retain an abundance of blastemal tissue
post-chemotherapy and these are stratified as high-risk blastemal
cases and have a poorer prognosis [4].
To date, there is a very limited understanding of the molecular
effects of therapy on Wilms’ tumor and the factors that produce
chemo resistance in this tumor. This is partly due to challenges in
the acquisition of paired pre-and post-treatment cases, as the
National Wilms tumor study group (NWTS) in North America
currently recommends primary surgical resection of Wilms’
tumors and even within the SIOP protocol, only a few countries
offer biopsy-based diagnosis prior to treatment.
Previous studies have focused on the assessment of histological
features in pre- versus post-treatment Wilms’ tumor cases [10,11].
Barroca (2010), found that the cytologic features of pre-treatment
fine needle biopsies did not have any bearing on the type and
extent of post-treatment regressive changes, however, all pre-
dominantly blastemal (high risk) post-treatment tumors corre-
sponded to pre-treatment cases with considerable blastemal
components and little necrosis or apoptosis. In order to explain
this phenomenon, Barroca suggested that two types of blastema
may occur in Wilms’ tumor and that each of these types exhibits
different chemotherapeutic sensitivities, proliferative properties
and abilities to undergo apoptosis or necrosis [11]. Although no
molecular analysis has been conducted to date that confirms this
theory.
In this study we performed a direct comparison of miRNA
profiles between post-treatment blastema, isolated from interme-
diate risk cases and the predominant blastemal component in high
risk cases and identified 10 miRNAs to be significantly up-
regulated in the high risk cases (Table 2). Of particular interest are
the up-regulation of miRNA 106b and miR-25 in the high risk
blastema. These miRNAs are members of the miR-106b,25
cluster located within intron 13 of the Mcm7 gene that has been
found to directly target a number of important tumor suppressor
pathways and may therefore be involved in the promotion of
cellular proliferation in high risk blastemal regions [12]. For
Figure 1. Unsupervised hierarchical clustering analysis. Of the 295 miRNAs, clustering analysis separates tumors into two clusters that clearly
segregate intermediate risk from high risk cases. Cluster A includes 13 post-treatment and 4 pre-treatment high risk cases, and cluster B includes 13
post-treatment and 14 pre-treatment intermediate risk cases. 4 sub-clusters further discriminate between pre- and post- treatment high risk (A1 and
A2) and pre- and post- treatment intermediate risk groups (B2 and B1).
doi:10.1371/journal.pone.0053417.g001
Table 2. miRNAs significantly up-regulated within the
blastemal component of post-treatment high risk cases [Post-
HR] when compared to post-treatment intermediate risk cases
[Post-IR-Bl].
miRNA ID Wilcoxon Rank [Corrected]
hsa.miR.551b 1.22E-04
hsa.miR.106b 2.75E-03
hsa.miR.24 4.09E-03
hsa.miR.542.3p 5.93E-03
hsa.miR.331.3p 8.49E-03
hsa.miR.223 8.49E-03
hsa.miR.518b 9.85E-03
hsa.miR.25 1.66E-02
hsa.miR.30b 2.27E-02
hsa.miR.523 4.13E-02
doi:10.1371/journal.pone.0053417.t002
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instance, miR-106b directly targets Retinoblastoma [RB], tumor
suppressor gene PTEN [13], as well as cyclin-dependent kinase
inhibitor p21/CDKN1A, [14] and pro-apoptotic Bcl-2 family
member BCL2L11 [Bim] [12]. The suppression of even one of
these pathways by the over-expression of miR-106b identified
here, has the potential to lead to a highly proliferative blastema
with reduced apoptosis and could thereby contribute to the
persistent and voluminous nature of this blastemal component in
high risk cases.
A number of recent publications suggest a significant role for
miRNAs in the molecular response to chemotherapy and
a selection of miRNAs has now been associated with chemo
resistant phenotypes in a range of cancer types [15,16]. Varying
levels of chemo sensitivity may be inferred by the influence of
miRNA up- or down-regulation on multiple mRNA targets and
subsequent protein expression. This may impact the cellular
response to anticancer agents by the dysregulation of survival
pathways, apoptotic capabilities, specific drug targets, DNA repair
systems or drug transport/metabolism [17,18]. However, it has
also been shown that the role of miRNAs in chemo resistance is
complex and often miRNAs are seen to have the opposite effects
towards similar anticancer agents in different cancer types [19]. A
number of differentially expressed miRNAs identified in this study
has been previously associated with chemo resistance. For
example, miR-15b, which is down-regulated in pre-treatment
high risk cases here, has previously been shown to play a role in
the development of multi-drug resistance in gastric cancer cells
through up-regulation of the Bcl2 protein and consequent
modulation of apoptotic pathways [20]. Alternatively, up-regula-
tion of miR-222 is also known to confer Tamoxifen drug-
Table 3. miRNAs significantly differentially expressed in post-treatment high-risk cases [Post-HR] when compared to post-
treatment intermediate-risk cases [Post-IR-NBl].
miRNA ID Wilcoxon Rank [Corrected]
miRNAs significantly down-regulated in post-treatment high-risk cases
hsa.miR.193a.5p 5.88E-05
hsa.miR.369.3p 5.88E-05
hsa.miR.369.5p 2.03E-02
hsa.miR.455.3p 8.00E-03
hsa.miR.455.5p 3.50E-02
hsa.miR.22 8.00E-03
hsa.miR.27a 1.10E-02
hsa.miR.654.3p 1.25E-02
hsa.miR.99a 1.49E-02
hsa.miR.574.3p 2.00E-02
hsa.miR.100 2.66E-02
hsa.miR.199b.5p 2.66E-02
hsa.miR.154 3.43E-02
hsa.miR.145 3.50E-02
hsa.miR.502.3p 4.58E-02
hsa.miR.494 4.58E-02
hsa.miR.199a.5p 4.58E-02
miRNAs significantly up-regulated in post-treatment high-risk cases
hsa.miR.483.5p 1.18E-04
hsa.miR.93 1.32E-03
hsa.miR.520e 2.85E-03
hsa.miR.628.5p 3.31E-03
hsa.miR.590.5p 4.09E-03
hsa.miR.491.5p 4.09E-03
hsa.miR.302a 5.74E-03
hsa.miR.17 1.10E-02
hsa.miR.106a 1.10E-02
hsa.miR.125a.5p 1.49E-02
hsa.miR.19a 2.00E-02
hsa.miR.106b 2.66E-02
hsa.miR.20a 4.58E-02
hsa.miR.367 4.58E-02
doi:10.1371/journal.pone.0053417.t003
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resistance in breast cancer cells through the negative regulation of
ERa and cell cycle inhibitor p27Kip1 [21,22].
In this study, in order to establish a potential miRNA marker
that may be predictive of chemotherapy response at biopsy stage,
we selected miRNAs where expression was altered between
intermediate and high risk cases not only after, but also already
before chemotherapy. The assumption here is that any marker that
might indicate a resistant tumor type prior to treatment would
remain detectable in high risk cases, as it is precisely the tumor
cells expressing this marker that would be chemo resistant.
Here we have highlighted a signature of 7 differentially
expressed miRNAs within pre-treatment diagnostic biopsy speci-
mens that may be predictive of chemo resistance in Wilms’ tumor.
These include the down-regulation of miR-193a.5p and miR-27a,
and the up-regulation of miR-483.5p, miR-628.5p, miR-590.5p,
miR-302a and miR-367. Of particular interest are the protein
targets of miR-27a, miR-302 and miR-483.5p. The down-
regulation of miR-27a has been linked to p-glycoprotein expres-
sion and has previously been reported to correlate with an up-
regulation of this protein and to contribute to chemo resistance
and relapse in leukemia patients [23]. The principal role of p-
glycoprotein is to mediate the elimination of toxic substances from
the cell. It is normally expressed in kidney cells and its expression
has been shown to be enhanced by Vincristine and Dactinomycin
chemotherapy in Wilms’ tumor patients [24].
It is plausible that the over-expression of miR-302 could
promote an embryonic stem cell-like cell cycle profile through the
suppression of cyclin D1 and Cdk4 [25]. This is particularly
applicable here as Wilms’ tumor likely arises from multipotent
embryonic kidney precursor cells and the expression of residual
multipotent properties may remain evident within regions of
persistent blastema that are a morphological feature of chemo-
resistant histology. In addition, miR-367 is part of the miR-302
cluster, and the miR-302/367 promoter is known to be
transcriptionally regulated by embryonic stem cell-specific tran-
scription factors [26]. These miRNAs are expressed at high levels
in post-treatment high risk cases in this study and may therefore
confer multipotent properties on these blastemal cells [27].
miR-483.5p upregulated in our high risk cases, is located within
intron 2 of the IGF2 gene on chromosome 11p15 [28] and is
thought to be co-expressed with its IGF2 host gene [29]. As the
expression of IGF2 has a particularly significant role in Wilms’
tumorigenesis and is often increased due to associated loss of
imprinting (LOI) events [30], the expression of this miRNA may
therefore also be frequently affected in tandem with IGF2 in
Wilms’ tumor, although this has not been studied to-date. miR-
483-5p has been shown to target the suppressor of cytokine signalling 3
(SOCS3) [31]. This results in the decreased expression of the
SOCS3 protein leading to sustained signaling of the Interleukin-6
(IL-6)/Signal transducers and activators of transcription 3 (STAT3)
cytokine pathways which stimulates growth and proliferation and
is potentially anti-apoptotic [32].
It is possible that one of the differentially expressed miRNAs
identified in this study may alone be the key component in
determining response to chemotherapy in Wilms’ tumor patients.
But, perhaps these miRNAs in fact work in tandem in regulating
the complex pathways of chemotherapeutic response and may
need to be considered as a miRNA signature in future studies. In
order to validate the miRNAs highlighted here, a prospective
study would need to be undertaken wherein the expression of these
miRNAs is assessed in patient biopsy samples. The suggestion here
is that miRNA markers identifiable in pre-treatment biopsy
specimens could allow for early prediction of potential drug
resistance and may be an important step towards customizing
current regimens in non-responsive Wilms’ tumor patients.
Supporting Information
Figure S1 Unsupervised hierarchical clustering of miR-
NAs including additional intermediate risk group with
selected blastemal components.
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Table 4. miRNAs significantly differentially expressed in both pre-treatment high risk group [Pre-HR] compared to pre-treatment
intermediate risk group [Pre-IR], and also in the post-treatment high-risk group [Post-HR] compared to the post-treatment
intermediate risk group [Post-IR-NBl].
PRE-TREATMENT POST-TREATMENT
miRNA ID
Expression in high risk
cases compared to
intermediate risk Wilcoxon Rank [Corrected]
Average miRNA
expression in
intermediate
risk cases
Average miRNA
expression in high
risk cases
Wilcoxon Rank
[Corrected]
hsa.miR.193a.5p Down regulated 5.88E-05 650.62 83.92 1.93E-01
hsa.miR.27a 1.10E-02 142.39 70.8 1.93E-01
hsa.miR.483.5p Up regulated 1.18E-04 54.08 792.19 1.93E-01
hsa.miR.628.5p 3.31E-03 4289.53 10867785.86 1.93E-01
hsa.miR.590.5p 4.09E-03 2.529 15.305 1.93E-01
hsa.miR.302a 5.74E-03 198.01 3763.27 1.93E-01
hsa.miR.367 4.58E-02 6.64 70.20 1.93E-01
doi:10.1371/journal.pone.0053417.t004
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